606 related articles for article (PubMed ID: 24018273)
1. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.
Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR
J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
3. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG
Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401
[TBL] [Abstract][Full Text] [Related]
4. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
5. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
[TBL] [Abstract][Full Text] [Related]
6. Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4.
Hanwell DG; McNeil B; Visan L; Rodrigues L; Dunn P; Shewen PE; Macallum GE; Turner PV; Vogel TU
J Immunother; 2013 May; 36(4):238-47. PubMed ID: 23603858
[TBL] [Abstract][Full Text] [Related]
7. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response.
Ji Q; Gondek D; Hurwitz AA
J Immunol; 2005 Aug; 175(3):1456-63. PubMed ID: 16034082
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
10. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
11. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
[TBL] [Abstract][Full Text] [Related]
12. Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy.
Tuettenberg A; Jonuleit H; Tüting T; Brück J; Knop J; Enk AH
Gene Ther; 2003 Feb; 10(3):243-50. PubMed ID: 12571632
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
Prins RM; Odesa SK; Liau LM
Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014
[TBL] [Abstract][Full Text] [Related]
14. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
[TBL] [Abstract][Full Text] [Related]
15. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
[TBL] [Abstract][Full Text] [Related]
16. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
[TBL] [Abstract][Full Text] [Related]
17. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18.
Yamanaka R; Xanthopoulos KG
DNA Cell Biol; 2005 May; 24(5):317-24. PubMed ID: 15869409
[TBL] [Abstract][Full Text] [Related]
18. Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.
Kalyanasundaram Bhanumathy K; Zhang B; Xie Y; Xu A; Tan X; Xiang J
J Gene Med; 2015; 17(8-9):153-60. PubMed ID: 26212685
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2.
Mendiratta SK; Thai G; Eslahi NK; Thull NM; Matar M; Bronte V; Pericle F
Cancer Res; 2001 Feb; 61(3):859-63. PubMed ID: 11221870
[TBL] [Abstract][Full Text] [Related]
20. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
